Interestingly, PET/CT with 68Ga-PSMA-targeted agents showed clinical relevance to detect sites of recurrence in PCa patients after radical prostatectomy with PSA levels lower than 1.0 ng/mL [29]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.